Influenza Virus Vaccine 2010-2011 Strain Selection Vaccines and Related Biological Products Advisory Committee (2/22/2010) Jerry P. Weir, Ph.D., Director.

Slides:

Advertisements

Similar presentations

18Feb2009VRBPAC Influenza Vaccine Manufacturing Industry Perspective for Vaccine Supply.

Advertisements

Influenza Vaccine Manufacturing

Candidate Vaccine Strains and Potency Reagents, Season Rajesh K. Gupta, Ph.D. Deputy Director, Division of Product Quality OVRR, CBER, FDA Prepared.

Preparation of Reference Influenza Viruses in Mammalian Cells: FDA Perspective Prepared for the Vaccines and Related Biological Products Advisory Committee.

Vaccines and Related Biological Products Advisory Committee 18 February 2009 Topic 2: Considerations and Implications for adding two B Strains to the Seasonal.

Vaccines and Related Biological Products

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

Lisa Grohskopf, MD, MPH Medical Officer Influenza Division Centers for Disease Control and Prevention U.S. Influenza Surveillance National Center for Immunization.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

Influenza Vaccine Responses Roland A. Levandowski, M.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee.

Influenza Vaccine Manufacturing Industry perspective for influenza vaccine supply VRBPAC, 27 February 2013 The FDA CBER requested this annual.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/27/2013) Jerry P. Weir, Ph.D., Director.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/28/2014) Jerry P. Weir, Ph.D., Director.

Influenza Vaccine Manufacturing Industry perspective for influenza vaccine supply VRBPAC, 28 February 2012 The FDA CBER requested this annual.

NS 2 Lipid Bilayer NA (Neuraminidase) HA (Hemagglutinin) M 2 (Ion channel) M 1 (Matrix protein) NP (Nucleocapsid) PB1, PB2, PA (Transcriptase complex)

INTRODUCTION TO INFLUENZA The (Ferret) Sneeze Heard Around The World: The Case Of The Bioengineered Bird Flu Case Study for AAC&U STIRS Project Jill M.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/25/2011) Jerry P. Weir, Ph.D., Director.

EPIDEMIOLOGY AND PREVENTION OF INFLUENZA. Introduction Unique epidemiology: – Seasonal attack rates of 10% to 30% – Global epidemics Influenza viruses.

EPIDEMIOLOGY AND PREVENTION OF INFLUENZA. Introduction Unique epidemiology: – Seasonal attack rates of 10% to 30% – Global pandemics Influenza viruses.

WHO PANDEMIC PHASES INTERPANDEMIC PERIOD Phase 1 Phase 2 PANDEMIC ALERT PERIOD Phase 3 Phase 4 Phase 5 PANDEMIC PERIOD Phase 6 POSTPANDEMIC PERIOD.

A Brief Update of Global Situation and Response to Pandemic Influenza A(H1N1) 2009 Wenqing Zhang MD Global Influenza Programme WHO HQ THE 3rd MEETING OF.

Martha Thompson, MPH Viral Isolation Team Leader Medical Virology Group Laboratory Services Section TX DSHS Influenza Surveillance Viral Isolation Laboratory.

Influenza Vaccine Development

Pandemic (H1N1) 2009 Influenza Vaccine Manufacturing Considerations Vaccines and Related Biological Products Advisory Committee (7/23/2009) Jerry P. Weir,

Influenza Vaccine Manufacturing Industry Perspective Tony Colegate Novartis Vaccines and Diagnostics Prepared by PhRMA Vaccine Technical Committee for.

VRBPAC 25 February 2011 Influenza Vaccine Manufacturing Industry Perspective for Vaccine Supply.

Vaccine Virus Selection W. Zhang 10 Jun 2011 Vientiane WHO WPR and SEAR NIC Meeting Improving influenza vaccine virus selection process - report from a.

Influenza Update September 2015

Review and Discussion Time line courtesy of:

Food and Drug Administration

Influenza Today Joseph Mester, Ph.D. September 24, 2009.

Update: “New Flu” Activity and Community Mitigation Diane Woolard, PhD, MPH Director, Division of Surveillance and Investigation Virginia Department of.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

Vaccines and Related Biological Products Advisory Committee Meeting July 23, 2009 Pandemic Influenza A (H1N1) Virology Update Nancy Cox, PhD Alexander.

1 Overview of the Division of Viral Products February 28, 2014 VRBPAC Discussion of the August 28, 2013 Site Visit for the Laboratory of Respiratory Viral.

VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE USPHS INFLUENZA VIRUS VACCINE STRAIN SELECTION

John R. LaMontagne Memorial Symposium on Pandemic Influenza Research April 4-5, 2005 Institute of Medicine Working Group One: Influenza Virulence and Antigenic.

Options for Influenza Vaccine Composition Summary of Data Options with Pros and Cons.

1 Licensure of Pandemic Influenza Vaccines: Demonstration of Effectiveness Vaccines and Related Biological Products Advisory Committee Meeting February.

Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (Q-Pan H5N1 Vaccine) Manufactured by GlaxoSmithKline Vaccines and Related Biological Products Advisory.

Ian Barr WHO Collaborating Centre for Reference & Research on Influenza, Melbourne (Now finally re-located at VIDRL) Influenza surveillance in Australia,

Update on Influenza Virus Surveillance Findings in 2008/09 Season in Northern Hemisphere Who Collaborating Center for Reference and Research on Influenza.

Influenza Virus Vaccine Composition Roland A. Levandowski, M.D. Division of Viral Products Prepared for Vaccines and Related Biological Products.

VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE CBER Regulatory Approaches & Activities To Support Licensure of Pandemic (H1N1) 2009 Vaccine.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

Samar Musmar,MD,FAAFP Vice Dean for Clinical Affairs An-Najah National University Faculty of Medicine Head, Medicine and Society Dep. Flu Vaccination in.

The New Influenza A/H1N1 Isabelle Thomas May 28-29, 2009 Brussels,

FDA’s Role in Facilitating the Availability of Influenza Vaccine Norman W. Baylor, Ph.D. Director, Office of Vaccines Research and Review CBER/FDA.

Influenza Branch VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE CBER, FDA February 16-17, 2005, Bethesda, MD Nancy COX, Ph.D. WHO COLLABORATING.

Update on Surveillance for Influenza Viruses with Pandemic Potential and Candidate Vaccine Viruses Nancy Cox, PhD CDC.

1 Influenza activity in the Southern Hemisphere Ian Barr WHO CC for Reference & Research on Influenza Melbourne The Melbourne WHO.

Virologia Applicata E.A. Influenza VIROLOGIA. Virologia Applicata E.A. Influenza The virus and its replication.

1 IMMUNE CORRELATES OF PROTECTION AGAINST INFLUENZA A VIRUSES IN SUPPORT OF PANDEMIC VACCINE DEVELOPMENT FDA/NIH/WHO Public Workshop, December 10-11, 2007.

Lisa Grohskopf, MD, MPH U.S. Influenza Surveillance Season National Center for Immunization & Respiratory Diseases Influenza Division U.S. Food.

Influenza Vaccine Responses Roland A. Levandowski, M.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee.

Options for Influenza Vaccine Composition Roland A. Levandowski, M.D. Division of Viral Products Prepared for Vaccines and Related Biological.

STATUS OF CANDIDATE VACCINE STRAINS AND POTENCY REAGENTS Zhiping Ye, M.D., Ph.D. FOOD AND DRUG ADMINISTRATION CENTER FOR BIOLOGICS EVALUATION AND RESEARCH.

1 Vaccines and Related Biological Products Advisory Committee Meeting FluBlok ® : Influenza Vaccine, Recombinant Hemagglutinin Applicant: Protein Sciences.

Carol Friedman, D.O. Associate Director for Adult Immunization Immunization Services Division National Center for Immunization and Respiratory Diseases.

Marketing Authorisation & Yearly Licence of Influenza Vaccines - „Mock-up” & Pre-Pandemic Influenza Vaccines Zsuzsanna Pauliny MD

1 Considerations in the Pre- and Early Pandemic Use of Influenza Vaccine Jesse L. Goodman, MD, MPH Center for Biologics Evaluation and Research, VRBPAC,

I Introduction to influenza

I Introduction to influenza Department of Health 2016 Vaccination Campaign Training workshop Presentation developed by the National Institute for Communicable.

Influenza Virologic Surveillance and Vaccine Strain Selection Xiyan Xu MD Deputy Director WHO Collaborating Center for Surveillance, Epidemiology and Control.

ACIP Recommendations Update for the U.S. Influenza Season

J. -H. Lin, S. -C. Chiu, J. -C. Cheng, H. -W. Chang, K. -L. Hsiao, Y

Presentation transcript:

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/22/2010) Jerry P. Weir, Ph.D., Director Division of Viral Products/OVRR/CBER/FDA

Purpose of Today’s VRBPAC Committee Discussion Review influenza surveillance and epidemiology data, antigenic characteristics of recent virus isolates, serological responses to current vaccines, and the availability of candidate vaccine strains and reagents Make recommendations for the strains of influenza A (H1N1 and H3N2) and B viruses to be included in influenza vaccines for use in the United States

Review of the Influenza Vaccine Strain Selection Process VRBPAC strain selection – 2/18/2009 Committee recommended the following strains for inclusion in U.S trivalent influenza vaccines A/Brisbane/59/2007 (H1N1)-like virus A/Brisbane/10/2007 (H3N2)-like virus B/Brisbane/60/2008-like virus (B/Victoria lineage) – change from vaccine recommendation Emergence of a novel H1N1 virus Rapid spread from North America throughout world from April 2009 WHO strain recommendation for development of vaccines against the pandemic (H1N1) 2009 virus on May 26, 2009 WHO declaration of a pandemic on June 11, 2009 VRBPAC – 7/23/2009 Committee convened to discuss pandemic H1N1 situation and planned clinical trials to support use of vaccines containing A/California/7/2009 (H1N1)v-like virus

Review of the Influenza Vaccine Strain Selection Process – Cont. Vaccine Approvals July 2009 – Strain change supplements for trivalent formulations approved (all 6 U.S. manufacturers) September 15, 2009 – Strain change supplements for pandemic monovalent formulation approved (4 U.S. manufacturers) November 11, 2009 – Strain change supplement for pandemic monovalent formulation approved (5 th U.S. manufacturer) WHO Recommendations for Southern Hemisphere 2010 – September 2009 A/California/7/2009 (H1N1)-like virus – change from NH vaccine recommendation A/Perth/16/2009 (H3N2)-like virus – change from NH vaccine recommendation B/Brisbane/60/2008-like virus

Types of Analyses Used for Vaccine Strain Selection Epidemiology of circulating strains Surveillance data from U.S. and around the world Antigenic relationships among contemporary viruses and candidate vaccine strains Hemagglutination inhibition (HI) tests using post-infection ferret sera Virus neutralization tests HI tests using panels of sera from humans receiving TIV Antigenic cartography Phylogenetic analyses of HA and NA genes Availability and characteristics of egg-derived vaccine strains and high-growth reassortants Availability of potency reagents for inactivated vaccines

WHO Recommendations for Influenza Vaccine Composition Northern Hemisphere: “It is recommended that the following viruses be used for influenza vaccines in the influenza season (northern hemisphere winter): an A/California/7/2009 (H1N1)-like virus an A/Perth/16/2009 (H3N2)-like virus a B/Brisbane/60/2008-like virus” “As in previous years, national or regional control authorities approve the composition and formulation of vaccines used in each country” VRBPAC and CBER for the U.S.

Committee Discussion Which influenza strains should be recommended for the antigenic composition of the influenza virus vaccine in the U.S.? Data to be considered includes: the epidemiology of circulating influenza viruses the antigenic characteristics of influenza virus strains currently circulating in human populations the serologic responses to circulating influenza viruses of persons immunized with current influenza virus vaccines the availability of suitable vaccine candidate strains

Options for Strain Composition for Influenza Vaccines Influenza A (H1N1) Retain current vaccine strain A/Brisbane/59/2007 (H1N1)-like virus e.g., A/Brisbane/59/2007; A/South Dakota/6/2007 Replace current vaccine strain with a pandemic A (H1N1) vaccine virus A/California/7/2009-like virus Other candidates? Influenza A (H3N2) Retain current strain A/Brisbane/10/2007 (H3N2)-like virus e.g., A/Brisbane/10/2007; A/Uruguay/716/2007 Replace current vaccine strain with the Southern hemisphere vaccine virus A/Perth/16/2009 (H3N2)-like virus e.g., A/Perth/16/2009; A/Wisconsin/15/2009 Other candidates? Influenza B Retain current B/Brisbane/60/2008-like virus (B/Victoria lineage) e.g., B/Brisbane/60/2008; B/Brisbane/33/2008 Replace current vaccine strain with alternative vaccine strain (B/Yamagata lineage) Candidates?